Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LIPO

Lipella Pharmaceuticals Inc

Sep 16 • 02:34PM ET

0.4030

Dollar change -0.0010
Percentage change -0.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	35.49%	Shs Outstand	6.05M	Perf Week	0.17%
Market Cap	3.22M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	2.34%	Shs Float	5.16M	Perf Month	-3.93%
Income	-4.14M	PEG	-	EPS next Q	-0.12	Inst Own	7.87%	Short Float	4.25%	Perf Quarter	-40.73%
Sales	0.51M	P/S	6.32	EPS this Y	28.57%	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-48.32%
Book/sh	0.22	P/B	1.80	EPS next Y	27.27%	ROA	-146.02%	Short Interest	0.22M	Perf Year	-80.58%
Cash/sh	0.15	P/C	2.71	EPS next 5Y	-	ROE	-171.56%	52W Range	0.32 - 2.71	Perf YTD	-60.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-189.86%	ROI	-243.13%	52W High	-85.13%	Beta	0.17
Dividend TTM	-	Quick Ratio	4.33	Sales past 5Y	20.14%	Gross Margin	-	52W Low	24.61%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	4.33	EPS Y/Y TTM	1.68%	Oper. Margin	-839.14%	RSI (14)	44.30	Volatility	13.17% 17.59%
Employees	7	Debt/Eq	0.05	Sales Y/Y TTM	34.99%	Profit Margin	-816.71%	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	53.94%	Payout	-	Rel Volume	0.18	Prev Close	0.40
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	27.89%	Earnings	Aug 28	Avg Volume	3.47M	Price	0.40
SMA20	-5.97%	SMA50	-17.91%	SMA200	-45.94%	Trades		Volume	490,300	Change	-0.25%

Aug-27-24 08:00AM	Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (GlobeNewswire)
Aug-22-24 05:00AM	Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research (GlobeNewswire)
Aug-21-24 05:00AM	Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference (GlobeNewswire)
Aug-12-24 06:52AM	Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial (Clinical Trials Arena)
05:00AM	Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial (GlobeNewswire)
04:05PM	Loading…
Aug-01-24 04:05PM	Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.05% -5.67%
08:00AM	Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-29-24 05:00AM	Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients (GlobeNewswire) +122.52%
May-31-24 08:00AM	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus (GlobeNewswire)
May-29-24 12:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 01:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
May-21-24 08:00AM	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b (GlobeNewswire)
Apr-17-24 08:00AM	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise (GlobeNewswire)
Apr-05-24 08:00AM	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire)
08:00AM	Loading…
Apr-03-24 08:00AM	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis (GlobeNewswire)
Mar-07-24 03:23PM	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease (GlobeNewswire)
Mar-05-24 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline (GlobeNewswire) -21.57%
Feb-20-24 08:00AM	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference (GlobeNewswire)
Dec-20-23 08:00AM	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished (GlobeNewswire)
Nov-12-23 08:20PM	Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD (Pharmaceutical Business Review)
Nov-10-23 08:00AM	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease (PR Newswire) -8.12%
Oct-25-23 04:05PM	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -24.89% -31.95%
Oct-24-23 08:00AM	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
08:30AM	Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference (ACCESSWIRE)
Oct-20-23 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus (PR Newswire) +29.81%
Sep-21-23 08:30AM	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology (PR Newswire)
Jun-13-23 08:30AM	Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders (NewMediaWire) +6.75%
May-15-23 09:15AM	Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (PR Newswire)
08:12AM	Loading…
May-14-23 08:12AM	Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022) (Simply Wall St.)
May-01-23 08:30AM	Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting (PR Newswire) -20.90%
Apr-17-23 08:30AM	Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite (PR Newswire)
Apr-05-23 08:30AM	Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent (PR Newswire)
Mar-31-23 08:00AM	Lipella Provides Business Update and Reports 2022 Financial Results (PR Newswire) +5.98%
Mar-16-23 08:30AM	Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association (PR Newswire) +36.07%
Mar-01-23 08:00AM	Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board (PR Newswire)
Jan-11-23 07:30AM	Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 (PR Newswire) +18.01%
Jan-09-23 08:00AM	Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco (PR Newswire)
Dec-22-22 04:05PM	Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million (PR Newswire) +12.78% -10.89%

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaufman Jonathan H	See remarks below.	May 14 '24	Buy	0.76	10,000	7,590	898,849	May 15 04:39 PM
Kaufman Jonathan H	See remarks below.	Mar 18 '24	Buy	0.79	30,000	23,649	863,849	Mar 19 06:21 PM
Kaufman Jonathan H	See remarks below.	Mar 19 '24	Buy	0.87	25,000	21,802	888,849	Mar 19 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIPO

Lipella Pharmaceuticals Inc

Upgrade your FINVIZ experience